sanostem

  • 1615 South Street, 93304

Stemedica Enters into a Global Distribution Agreement with Life Technologies

By /

New Stem Cell Therapy May Transform Heart Failure Treatment

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and clinical development, announced today they have entered into a Global Distribution Agreement with Life Technologies Corporation. Under the terms of this agreement, Life Technologies will exclusively offer Stemedica’s ischemic tolerant allogeneic adult mesenchymal stem cells (itMSCs) and neural stem cells (itNSCs) for sale worldwide to research, academic institutions and corporations both in the United States and internationally. Stemedica stem cell lines will be sold under the brand name Gibco® and will be available to purchase for research initiatives beginning Q2, 2013. The label will also carry the name of Stemedica as the manufacturer of the cell lines.

Life Technologies is a global biotechnology company with customers in more than 180 countries, providing more than 50,000 end-to-end solutions for customers in the fields of scientific research, genetic analysis and applied sciences. The Company’s systems, reagents and consumables represent some of the most cited brands in scientific research. Life Technologies employs approximately 10,000 people and upholds its ongoing commitment to innovation with more than 5,000 patents and exclusive licenses. The Company had sales of $3.8 billion in 2012.

“We are honored to be associated with a company of the caliber of Life Technologies.” stated Maynard Howe, PhD, CEO and Vice Chairman of Stemedica. “The goal of our collaboration is to serve the worldwide market of corporate research and academic institutions. Providing multiple stem cell products using a patented large-scale Reduced Oxygen Tension manufacturing process (Patent #8,420,394) to scientists who are conducting or plan to conduct stem cell research will accelerate new discoveries and ultimately enable physicians to treat medical conditions and diseases for which there are no effective treatments.”
According to Nikolai Tankovich, MD, PhD, President and Chief Medical Officer of Stemedica, “This collaboration between Stemedica and Life Technologies creates a unique opportunity for all researchers and scientists around the world to advance their discoveries. This acceleration is possible because Stemedica’s stem cell products are manufactured under controlled cGMP conditions allowing for uniform reproducibly manufactured cells to support controlled research. essor of Medicine. He joined the faculty of the University of Pennsylvania in 1996.

About Stemedica

Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its clinical trials for ischemic stroke, acute myocardial infarct, and cutaneous photoaging. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The Company is headquartered in San Diego, California.

Scroll to Top